Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 8 Cost-effectiveness. Estimated cost-effectiveness ratio as the fraction of active cases vary, with all parameters otherwise equal to the base case scenario. All QALYs and costs are discounted at three percent per year; costs are listed in 2004 U.S. dollars. The cost-effectiveness ratios are based on the assumption that all active cases and latently infected individuals (ATS class 2 and class 4) are eligible for treatment.

From: Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants

Fraction of active cases 40% TB4s 60% TB4s
  Cost per QALY saved Cost per case averted Cost per QALY saved Cost per case averted
0% $72 000 $72 000 $64 000 $66 000
0.5% $47 000 $57 000 $45 000 $53 000
1.0% $30 000 $41 000 $31 000 $41 000
1.5% $17 000 $27 000 $19 000 $29 000
2.0% $7 000 $12 000 $10 000 $17 000
2.5% cost saving cost saving $3000 $5 000
3.0% cost saving cost saving cost saving cost saving